Long-term survival follow-up data show that GPER expression is associated with a decreased response rate to tamoxifen therapy in BC patients,67, 68, 69, 70 and this finding was supported by a public dataset71 for the discovery and validation of survival-associated GPER genes in high-risk lymph node-positive ER+BC, who receive tamoxifen treatment (Fig. 3A, B). The gene discussed is GPER1; the disease is breast cancer.